---
categories: i
title: "In a pandemic boom callback David Lius preclinical gene editing startup debuts on Nasdaq with 175M IPO  Endpoints News"
---
In a pandemic boom callback, David Liu"s preclinical gene editing startup debuts on Nasdaq with $175M IPO&nbsp;&nbsp;Endpoints NewsPrime time for IPO as gene editing biotech goes public with $175M&nbsp;&nbsp;FierceBiotechBiotech firm Prime Medicine valued at $1.8 bln in strong debut&nbsp;&nbsp;Reute